Hercules Capital HTGZ 深 沪

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics submitted a Biologics License Application (BLA) for sonelokimab to treat moderate-to-severe hidradenitis suppurativa (HS) in adults and adolescents, marking a key step toward U.S. approval. Positive results from the Phase 3 IZAR-1 trial in psoriatic arthritis (PsA) were reported, with all clinical endpoints met for sonelokimab 60 mg with induction. Enrollment was completed in the Phase 3 IZAR-2 trial in PsA, with initi...

11-04 12:00

Hercules Capital Announces Q3 Cash Distribution and Growth

An announcement from Hercules Capital, Inc. ( ($HTGC) ) is now available. On Oc...

10-30 05:22

Hercules Capital Q3 EPS $0.47, Inline, Sales $140.100M Miss $143.178M Estimate

Hercules Capital (NYSE:HTGC) reported quarterly earnings of $0.47 per share which met the analyst consensus estimate. This is a 4.08 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $140.100 million which missed the analyst con...

10-30 04:09

赫库利斯资本2026财年第三季度财报：净投资收益对基础分红的覆盖率达118%

Hercules Capital（NYSE: HTGC）公布2026年第三季度净投资收益为8730万美元，即每股0.47美元，对其基础现金派息的覆盖率为118%。今年前九个月，总投资收益增长9.0%至4.308亿美元，净投资收益增长5.4%至2.684亿美元。年初至今承诺投资额达到34.4亿美元，实际放款总额达19.3亿美元。资产管理规模增长17.7%至约65亿美元，流动资金（包含投资顾问管理的基金）超过10亿美元，按GAAP计算的净杠杆率为109.0%。

10-29 20:22

Hercules Capital Prices Upsized Public Offering Of $400M, 6.70% Notes Due 2029

Hercules Capital, Inc. (NYSE: HTGC) ("Hercules," "Hercules Capital," or the "Company"), today announced that it has priced an underwritten public offering of $400.0 million in aggregate principal amount of 6.70% notes due October 2029 (the "Notes"). The closing of the transaction is subject to custo...

10-06 04:11

Hercules Capital Adds Independent Director to Board

The latest announcement is out from Hercules Capital, Inc. ( ($HTGC) ). On Sept...

09-18 04:52

UBS Upgrades Hercules Capital to Buy, Raises Price Target to $18.5

UBS analyst Melissa Wedel upgrades Hercules Capital (NYSE:HTGC) from Neutral to Buy and raises the price target from $15.5 to $18.5.

09-01 21:00

Wall Street's Most Accurate Analysts Weigh In On 3 Financial Stocks With Over 9% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. Benzinga readers can review the latest analyst takes on their favorite stocks by v...

08-10 19:26

MoonLake Immunotherapeutics GAAP EPS of -$0.84

MoonLake Immunotherapeutics press release (MLTX): Q2 GAAP EPS of -$0.84. MoonLake ended the second quarter with $537.0 million in cash, cash equivalents and short-term marketable debt securities and e...

08-10 19:12

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

08-10 11:00